Should the approach to surgery be similar to the decisions around factor administration in children with mild hemophilia A? One difference is that unlike mild HA patients who can sometimes use desmopressin as a way to increase their baseline FVIII level, in severe HA patients on emicizumab, additional factor administration before and possible following surgery will need to be considered if higher FVIII levels are needed for the surgical procedure. The gene discussed is F8; the disease is hemophilia A.